{"schema_version":"secwatch.filing_event.v1","accession":"0000879169-26-000040","form_type":"8-K","ticker":"INCY","cik":"0000879169","company_name":"INCYTE CORP","filed_at":"2026-06-08T11:05:51+00:00","discovered_at":"2026-06-08T11:10:01.258858+00:00","generated_at":"2026-06-08T11:12:14.610952+00:00","sec_items":["8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Incyte to acquire Vega Therapeutics for $1.25B upfront; total up to $2.0B","bullets":["Acquires Vega Therapeutics from Star Therapeutics; adds VGA039, a Phase 3 anti-Protein S mAb for von Willebrand disease.","Star receives $1.25B upfront; up to $750M in sales milestones for total consideration of $2.0B.","VGA039 has Breakthrough Therapy, Fast Track, and orphan drug designations from FDA; Phase 3 VIVID-6 trial ongoing.","Transaction approved by both boards; expected to close in Q3 2026 subject to HSR review.","Incyte expects a ~$1.25B R&D charge in Q3 and full year 2026 GAAP and non-GAAP results."],"urls":{"canonical":"https://secwatch.observer/filing/0000879169-26-000040","json":"https://secwatch.observer/filing/0000879169-26-000040.json","markdown":"https://secwatch.observer/filing/0000879169-26-000040.md","text":"https://secwatch.observer/filing/0000879169-26-000040.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/879169/000087916926000040/0000879169-26-000040-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/879169/000087916926000040/incy-20260608.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T11:12:14.610952+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}